Joint research conducted in Paris at the Department of Pathology, Sorbonne University, and the Department of Oncology, Georges Pompidou Hospital, indicates that the use of tumour budding as a prognostic biomarker in colon cancer could influence disease-free and overall survival for patients diagnosed at stage III. Defined as "a single cancer cell of up to four cancer cells at the tumour invasive margin", tumour budding was applied to 1,048 stage III colon cancer patients in the joint Paris post-hoc study. While the study authors acknowledge that further research is required, their findings do support the notion that "tumour budding seems to provide additional and clinically relevant prognostic information beside risk groups and Immunoscore."
To learn more about this study, click here.
Source mentioned: Basile D, Broudin C, Emile JF, et al. Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Annals of Oncology; Published online 16 March 2022. DOI: https://doi.org/10.1016/j.annonc.2022.03.002
No comments:
Post a Comment